David R Riddell

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. doi request reprint Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels
    David R Riddell
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA
    J Neurosci 28:11445-53. 2008
  2. doi request reprint Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease
    Robert L Martone
    Wyeth Research, Departments of Discovery Neuroscience, Princeton, New Jersey 08543, USA
    J Pharmacol Exp Ther 331:598-608. 2009
  3. ncbi request reprint The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
    David R Riddell
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Mol Cell Neurosci 34:621-8. 2007
  4. doi request reprint Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease
    Scott C Mayer
    Chemical and Screening Sciences, and Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    J Med Chem 51:7348-51. 2008
  5. doi request reprint (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor
    Derek C Cole
    Chemical and Screening Sciences, Wyeth Research, Pearl River, NY 10965, USA
    Bioorg Med Chem Lett 19:926-9. 2009

Collaborators

Detail Information

Publications5

  1. doi request reprint Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels
    David R Riddell
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA
    J Neurosci 28:11445-53. 2008
    ....
  2. doi request reprint Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease
    Robert L Martone
    Wyeth Research, Departments of Discovery Neuroscience, Princeton, New Jersey 08543, USA
    J Pharmacol Exp Ther 331:598-608. 2009
    ..In healthy human volunteers, oral administration of a single dose of GSI-953 produces dose-dependent changes in plasma Abeta levels, confirming pharmacodynamic activity of GSI-953 in humans...
  3. ncbi request reprint The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
    David R Riddell
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Mol Cell Neurosci 34:621-8. 2007
    ..These data demonstrate that LXR agonists do not directly inhibit APP processing but rather facilitate the clearance of Abeta42 and may represent a novel therapeutic approach to Alzheimer's disease...
  4. doi request reprint Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease
    Scott C Mayer
    Chemical and Screening Sciences, and Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    J Med Chem 51:7348-51. 2008
    ..Further side chain modification afforded the potent Notch-1-sparing GSI begacestat (5), which was selected for development for the treatment of Alzheimer's disease...
  5. doi request reprint (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor
    Derek C Cole
    Chemical and Screening Sciences, Wyeth Research, Pearl River, NY 10965, USA
    Bioorg Med Chem Lett 19:926-9. 2009
    ..5-fold) gamma-secretase inhibitor (S)-N-(5-chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol 7.b.2 (Abeta(40/42) EC(50)=28 nM), which is efficacious in reduction of Abeta production in vivo...